Opening Up New Food-and-Pharmaceutical Markets Through Biomarker Technology
First written in FY2016. 25 of 27 entries say "Restated". Latest entry: 2026-09-24.
0 other companies' latest entry also says "Advanced".
- 2026-09-24AdvancedBusiness Alliances
「Through this agreement, we will leverage the research and development and manufacturing base of the Sichuan Kelun Pharmaceutical Group and our group’s expertise in clinical research and functional evaluation developed in Japan to promote the commercialization of new functional materials and pursue business expansion, including cross-border e-commerce into the Chinese market, with 思尼特 facilitating communication and coordination between Japan and China.」
The existing policy of researching and developing functional materials and building evidence has progressed into concrete initiatives, including a framework agreement for joint research with a major Chinese pharmaceutical group, product development and commercialization, and expansion into the Chinese market. - FY2026RestatedAnnual report
「Based on evidence (scientific grounds) generated by leveraging university research results, the Group will develop and provide services and products that contribute to maintaining and improving public health and using healthcare resources efficiently.」
The Group continues to pursue its basic policy of providing health and healthcare-related services and products based on university research results and evidence. - 2026-08-12RestatedRevision of earnings forecasts
「Under these business conditions, our group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technologies, its broad network in the medical and healthcare communities, and other resources to provide healthcare-related services ranging from prevention to treatment through the use of medical DX, thereby contributing to the creation of a self-medication society.」
The company has reconfirmed its basic policy of using university-originated biomarker technologies, evidence and medical and healthcare networks to provide medical DX and healthcare services ranging from prevention to treatment. - FY2024-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2024-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2024-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2023RestatedAnnual report
「The Group will develop and provide services and products based on evidence (scientific grounds) generated using university research成果, contributing to the maintenance and improvement of public health and the efficient use of healthcare resources.」
The Group continues to pursue its basic policy of using university research results, evidence and medical and healthcare networks to provide products and services in the pharmaceutical, food, cosmetics and healthcare fields. - FY2023-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2023-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2023-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2022-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its basic policy of using university-developed biomarker technologies, evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2022-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2021-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2021-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group has reaffirmed its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2021-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2020RestatedAnnual report
「The Group will develop and provide services and products based on evidence (scientific grounds) generated using university research成果, contributing to the maintenance and improvement of public health and the efficient use of healthcare resources.」
The Group reconfirms its basic policy of using university research成果, evidence and its healthcare network to develop and provide products and services in pharmaceuticals, food, cosmetics and healthcare. - FY2020-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2020-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2019-Q3RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2019-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2019-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue its policy of using university-developed biomarker technologies, know-how in building evidence and healthcare networks to develop products and services in multiple fields and expand its business. - FY2018RestatedAnnual report
「The Group will leverage its strengths, including its advanced medical expertise and R&D capabilities, its know-how and experience in obtaining and establishing the authority of evidence, its network of physicians and physician organizations, and the neutrality and public-interest orientation associated with being a university-originated company, to develop and provide services and products that contribute to maintaining and improving public health and using healthcare resources efficiently.」
The Group reconfirms its policy of using university-originated biomarker technology, R&D capabilities, evidence-building expertise and its healthcare network to expand across pharmaceuticals, food, cosmetics and healthcare. - FY2018-Q2RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue business expansion by applying university-originated biomarker technology, evidence and its healthcare network to product and service development across multiple fields. - FY2018-Q1RestatedAnnual report
「Against this backdrop, the Group intends to expand its business by leveraging its track record and expertise in building and applying evidence based on university-originated biomarker technology, as well as its broad network in the medical and healthcare communities, to develop and provide products and services that address social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to pursue business expansion by applying university-originated biomarker technology, evidence and its healthcare network to product and service development across multiple fields. - FY2017-Q3RestatedAnnual report
「The Group plans to expand its business by leveraging its track record and know-how in building and applying evidence based on university-originated biomarker technology, as well as its extensive networks in the medical and healthcare communities, to develop and provide products and services that meet social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group continues to use university-originated biomarker technology, evidence and its healthcare network to develop products and services across multiple fields and expand its business. - FY2017-Q1RestatedAnnual report
「The Group plans to expand its business by leveraging its track record and know-how in building and applying evidence based on university-originated biomarker technology, as well as its extensive networks in the medical and healthcare communities, to develop and provide products and services that meet social needs across a range of fields, including pharmaceuticals, food, cosmetics and healthcare-related services.」
The Group reaffirmed its policy of using university-originated biomarker technology, evidence and healthcare networks to develop products and services across multiple fields and expand the business. - FY2016First statedAnnual report
「By incorporating university research成果, the Group conducts research and development into biomarkers, which are indicators used to objectively and quantitatively assess physical and disease conditions, and biometric assessment systems that use them. By applying this technology, the Group seeks to develop new markets for foods, pharmaceuticals and other products for pathological conditions and diseases for which effective food or pharmaceutical products could not previously be developed because no appropriate assessment methods existed.」
The business model is based on university research成果 and proprietary know-how, using assessment systems to develop new markets for foods, pharmaceuticals and other products.